The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis
Abstract
Brain imaging characteristics of MOG antibody disease are largely unknown and it is unclear whether they differ from those of multiple sclerosis and AQP4 antibody disease. The aim of this study was to identify brain imaging discriminators between those three inflammatory central nervous system diseases in adults and children to support diagnostic decisions, drive antibody testing and generate disease mechanism hypotheses. Clinical brain scans of 83 patients with brain lesions (67 in the training and 16 in the validation cohort, 65 adults and 18 children) with MOG antibody (n = 26), AQP4 antibody disease (n = 26) and multiple sclerosis (n = 31) recruited from Oxford neuromyelitis optica and multiple sclerosis clinical services were retrospectively and anonymously scored on a set of 29 predefined magnetic resonance imaging features by two independent raters. Principal component analysis was used to perform an overview of patients without a priori knowledge of the diagnosis. Orthogonal partial least squares discriminant analysis was used to build models separating diagnostic groups and identify best classifiers, which were then tested on an independent cohort set. Adults and children with MOG antibody disease frequently had fluffy brainstem lesions, often located in pons and/or adjacent to fourth ventricle. Children across all conditions showed more frequent bilateral, large, brainstem and deep grey matter lesions. MOG antibody disease spontaneously separated from multiple sclerosis but overlapped with AQP4 antibody disease. Multiple sclerosis was discriminated from MOG antibody disease and from AQP4 antibody disease with high predictive values, while MOG antibody disease could not be accurately discriminated from AQP4 antibody disease. Best classifiers between MOG antibody disease and multiple sclerosis were similar in adults and children, and included ovoid lesions adjacent to the body of lateral ventricles, Dawson's fingers, T1 hypointense lesions (multiple sclerosis), fluffy lesions and three lesions or less (MOG antibody). In the validation cohort patients with antibody-mediated conditions were differentiated from multiple sclerosis with high accuracy. Both antibody-mediated conditions can be clearly separated from multiple sclerosis on conventional brain imaging, both in adults and children. The overlap between MOG antibody oligodendrocytopathy and AQP4 antibody astrocytopathy suggests that the primary immune target is not the main substrate for brain lesion characteristics. This is also supported by the clear distinction between multiple sclerosis and MOG antibody disease both considered primary demyelinating conditions. We identify discriminatory features, which may be useful in classifying atypical multiple sclerosis, seronegative neuromyelitis optica spectrum disorders and relapsing acute disseminated encephalomyelitis, and characterizing cohorts for antibody discovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Orthogonal projections to latent structures (O‐PLS)
Trygg, J., & Wold, S. (2002) · Journal of Chemometrics · doi:10.1002/cem.695 · Cited by 2,447
The spectrum of neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Lucchinetti, C. F., Pittock, S. J., & Weinshenker, B. G. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70216-8 · Cited by 2,179
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders
Sato, D. K., Callegaro, D., Lana-Peixoto, M. A., Waters, P. J., Jorge, F. M. D. H., Takahashi, T., Nakashima, I., Apostolos-Pereira, S. L., Talim, N., Simm, R. F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000101 · Cited by 850
Linington, C., Bradl, M., Lassmann, H., Brunner, C., & Vass, K. (1988) · PubMed · Cited by 708
MRI characteristics of neuromyelitis optica spectrum disorder: An international update
Kim, H. J., Paul, F., Lana-Peixoto, M. A., Tenembaum, S., Asgari, N., Palace, J., Klawiter, E. C., Sato, D. K., de Seze, J., Wuerfel, J., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001367 · Cited by 664
Self-citationKitley, J., Waters, P., Woodhall, M., Leite, M. I., Murchison, A., George, J., Küker, W., Chandratre, S., Vincent, A., & Palace, J. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5857 · Cited by 597 · cited 9×
“, 2015a), were present in MOG antibody patients in our study and have been also reported previously (Kitley et al., 2014).”
BackgroundResultInfluentialSelf-citationSerologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG assays
Waters, P. J., McKeon, A., Leite, M. I., Rajasekharan, S., Lennon, V. A., Villalobos, A., Palace, J., Mandrekar, J. N., Vincent, A., Bar-Or, A., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318248dec1 · Cited by 526
Self-citationMyelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype
Kitley, J., Woodhall, M., Waters, P., Leite, M. I., Devenney, E., Craig, J., Palace, J., & Vincent, A. (2012) · Neurology · doi:10.1212/wnl.0b013e31826aac4e · Cited by 445
Self-citationSelf-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein
O'Connor, K. C., McLaughlin, K. A., De Jager, P. L., Chitnis, T., Bettelli, E., Xu, C., Robinson, W. H., Cherry, S. V., Bar-Or, A., Banwell, B., et al. (2007) · Nature Medicine · doi:10.1038/nm1488 · Cited by 416
Brunner, C., Lassmann, H., Waehneldt, T. V., Matthieu, J., & Linington, C. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb10930.x · Cited by 409
MOG cell-based assay detects non-MS patients with inflammatory neurologic disease
Waters, P., Woodhall, M., O'Connor, K. C., Reindl, M., Lang, B., Sato, D. K., Juryńczyk, M., Tackley, G., Rocha, J., Takahashi, T., et al. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000089 · Cited by 390
Self-citationSchluesener, H. J., Sobel, R. A., Linington, C., & Weiner, H. L. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.12.4016 · Cited by 371
Reindl, M., Linington, C., Brehm, U., Egg, R., Dilitz, E., Deisenhammer, F., Poewe, W., & Berger, T. (1999) · Brain · doi:10.1093/brain/122.11.2047 · Cited by 347
Baumann, M., Sahin, K., Lechner, C., Hennes, E. M., Schanda, K., Mader, S., Karenfort, M., Selch, C., Hausler, M., Eisenkolbl, A., et al. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308346 · Cited by 314
Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis
Bernard, C. C. A., Johns, T. G., Slavin, A., Ichikawa, M., Ewing, C., Liu, J., & Bettadapura, J. (1997) · Journal of Molecular Medicine · doi:10.1007/s001090050092 · Cited by 270
Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS
Kim, S.-M., Woodhall, M. R., Kim, J.-S., Kim, S.-J., Park, K. S., Vincent, A., Lee, K.-W., & Waters, P. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000163 · Cited by 232
Self-citationZhou, D., Srivastava, R., Nessler, S., Grummel, V., Sommer, N., Brück, W., Hartung, H.-P., Stadelmann, C., & Hemmer, B. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607242103 · Cited by 231
Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children
Hacohen, Y., Absoud, M., Deiva, K., Hemingway, C., Nytrova, P., Woodhall, M., Palace, J., Wassmer, E., Tardieu, M., Vincent, A., et al. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000081 · Cited by 230
Self-citationAutoantibodies to MOG in a distinct subgroup of adult multiple sclerosis
Spadaro, M., Gerdes, L. A., Krumbholz, M., Ertl-Wagner, B., Thaler, F. S., Schuh, E., Metz, I., Blaschek, A., Dick, A., Brück, W., et al. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000257 · Cited by 206
Waubant, E., Chabas, D., Okuda, D. T., Glenn, O., Mowry, E., Henry, R. G., Strober, J. B., Soares, B., Wintermark, M., & Pelletier, D. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.135 · Cited by 201
Xiao, B.-G., Linington, C., & Link, H. (1991) · Journal of Neuroimmunology · doi:10.1016/0165-5728(91)90014-x · Cited by 197
Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton
Dale, R. C., Tantsis, E. M., Merheb, V., Kumaran, R.-Y. A., Sinmaz, N., Pathmanandavel, K., Ramanathan, S., Booth, D. R., Wienholt, L. A., Prelog, K., et al. (2014) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000012 · Cited by 173
Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype
Pröbstel, A.-K., Rudolf, G., Dornmair, K., Collongues, N., Chanson, J.-B., Sanderson, N. S., Lindberg, R. L., Kappos, L., de Seze, J., & Derfuss, T. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0256-1 · Cited by 169
Marta, C. B., Oliver, A. R., Sweet, R. A., Pfeiffer, S. E., & Ruddle, N. H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504979102 · Cited by 155
Jarius, S., Metz, I., König, F. B., Ruprecht, K., Reindl, M., Paul, F., Brück, W., & Wildemann, B. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458515622986 · Cited by 116
Overlapping CNS inflammatory diseases: differentiating features of NMO and MS
Juryńczyk, M., Craner, M. J., & Palace, J. A. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308984 · Cited by 112
Self-citationvon Büdingen, H. ‐., Hauser, S. L., Fuhrmann, A., Nabavi, C. B., Lee, J. I., & Genain, C. P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122092499 · Cited by 96
A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis
Dickens, A. M., Larkin, J. R., Griffin, J. L., Cavey, A., Matthews, L., Turner, M. R., Wilcock, G. K., Davis, B. G., Claridge, T. D. W., Palace, J. A., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000905 · Cited by 81
Self-citationIkeda, K., Kiyota, N., Kuroda, H., Sato, D. K., Nishiyama, S., Takahashi, T., Misu, T., Nakashima, I., Fujihara, K., & Aoki, M. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514551455 · Cited by 71
Myelin oligodendrocyte glycoprotein antibodies and multiple sclerosis in healthy young adults
Wang, H., Munger, K. L., Reindl, M., O’Reilly, É., Levin, L. I., Berger, T., & Ascherio, A. (2008) · Neurology · doi:10.1212/01.wnl.0000316195.52001.e1 · Cited by 67
Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes
Juryńczyk, M., Weinshenker, B. G., Akman‐Demir, G., Asgari, N., Barnes, D., Boggild, M., Chaudhuri, A., D'hooghe, M. B., Evangelou, N., Geraldes, R., et al. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7952-8 · Cited by 67
Self-citationAn integrated functional genomic study of acute phenobarbital exposure in the rat
Waterman, C. L., Currie, R. A., Cottrell, L., Dow, J., WRIGHT, J. A., Waterfield, C. J., & Griffin, J. L. (2010) · BMC Genomics · doi:10.1186/1471-2164-11-9 · Cited by 61
Haase, C. G., & Schmidt, S. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01949-8 · Cited by 50
Makino, T., Ito, S., Mori, M., Yonezu, T., Ogawa, Y., & Kuwabara, S. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458512454772 · Cited by 41
Marta, C. B., Bansal, R., & Pfeiffer, S. E. (2008) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.02.002 · Cited by 17
Cited by
Banwell, B., Bennett, J. L., Marignier, R., Kim, H. J., Brilot, F., Flanagan, E. P., Ramanathan, S., Waters, P., Tenembaum, S., Graves, J. S., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00431-8 · Cited by 1,246
Self-citationMOG encephalomyelitis: international recommendations on diagnosis and antibody testing
Jarius, S., Paul, F., Aktas, O., Asgari, N., Dale, R. C., de Seze, J., Franciotta, D., Fujihara, K., Jacob, A., Kim, H. J., et al. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1144-2 · Cited by 747
Self-citationClinical presentation and prognosis in MOG-antibody disease: a UK study
Jurynczyk, M., Messina, S., Woodhall, M. R., Raza, N., Everett, R., Roca-Fernandez, A., Tackley, G., Hamid, S., Sheard, A., Reynolds, G., et al. (2017) · Brain · doi:10.1093/brain/awx276 · Cited by 740
Self-citationMyelin in the Central Nervous System: Structure, Function, and Pathology
Stadelmann, C., Timmler, S., Barrantes-Freer, A., & Simons, M. (2019) · Physiological Reviews · doi:10.1152/physrev.00031.2018 · Cited by 728
Myelin oligodendrocyte glycoprotein antibodies in neurological disease
Reindl, M., & Waters, P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0112-x · Cited by 626
Self-citation
Metadata
- Authors
- Jurynczyk, M., Geraldes, R., Probert, F., Woodhall, M. R., Waters, P., Tackley, G., DeLuca, G., Chandratre, S., Leite, M. I., Vincent, A., & Palace, J.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-02-24
- Volume
- 140
- Issue
- 3
- Pages
- 617-627
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2598701066
- Cited by
- 265
- References
- 35
- FWCI
- 22.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.